Thanks to Julie Shilane and Maike Haehle for an excellent easy-to-read summary of feedback from Specialists' assessments of MDS-related research presented at ASH 2012. 
Check it out on the MDS Beacon...
http://www.mdsbeacon.com/news/2013/0...#comment-23526
__________________
Ric: Low-risk MDS (blasts <4%); 4 cycles Revlimid no positive response; PRBC transfusion dependent; so far, 392'units' over 8 3/4 years; BMB #4 (15/04/01) shows evolution to AML (blasts 20-30%  ) 47,XY,del(5) (q22q35),+21[24][cp24]/46,XY(1).
Last edited by riccd2001 : Sat Jan 5, 2013 at 08:05 PM.
Reason: Added link
|